IRMD IRADIMED CORP
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1325618 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.0%
TTM net income YoY13.2%
TTM EPS YoY13.3%
Revenue 3-yr CAGR12.4%
Net income 3-yr CAGR13.7%
Margins
Gross margin75.5%
Operating margin32.3%
Net margin26.8%
FCF margin29.3%
EBITDA margin33.9%
Returns
ROE23.4%
ROA20.3%
ROIC (approx.)52.3%
Asset turnover0.76x
Leverage & solvency
Liabilities / assets12.1%
Debt / equity0.00x
Current ratio8.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.13x
Accruals ratio-2.7%
Payout ratio67.7%
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $83.81M | $73.24M |
| Cost of revenue | $19.49M | $16.89M |
| Gross profit | $64.32M | $56.35M |
| R&D expense | $2.98M | $2.83M |
| SG&A expense | $17.78M | $15.94M |
| Operating income | $26.15M | $21.96M |
| Pretax income | $28.36M | $24.27M |
| Income tax | $5.88M | $5.04M |
| Net income | $22.48M | $19.23M |
| EBITDA | $27.31M | $22.78M |
| EPS (basic) | 1.77 | 1.52 |
| EPS (diluted) | 1.75 | 1.50 |
| Weighted avg. shares (diluted) | 12.85M | 12.78M |
| Balance sheet | ||
| Cash & equivalents | $51.16M | $52.23M |
| Receivables | $13.67M | $10.56M |
| Inventory | $11.62M | $10.40M |
| Current assets | $81.20M | $75.24M |
| PP&E, net | $23.86M | $16.81M |
| Intangibles | $3.38M | $3.10M |
| Total assets | $108.78M | $98.33M |
| Current liabilities | $10.18M | $8.51M |
| Total liabilities | $14.16M | $11.51M |
| Shareholders' equity | $94.62M | $86.82M |
| Shares outstanding | 12.78M | 12.71M |
| Cash flow statement | ||
| Operating cash flow | $24.95M | $25.62M |
| Capital expenditure | $7.76M | $8.01M |
| Free cash flow | $17.18M | $17.62M |
| Investing cash flow | -$8.42M | -$8.82M |
| Financing cash flow | -$17.60M | -$14.34M |
| Depreciation & amortization | $1.17M | $818,000 |
| Stock-based compensation | $2.92M | $2.52M |
| Dividends paid | $15.04M | $13.68M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.